Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Clinical trial NCT04506138 · UNKNOWN
Trial details
- NCT number
- NCT04506138
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-11
- Primary completion
- 2025-12-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.